• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trial.肾功能不全对中国患者华法林抗凝效果及安全性的影响:一项随机对照研究的分析。
Naunyn Schmiedebergs Arch Pharmacol. 2021 Jun;394(6):1275-1283. doi: 10.1007/s00210-020-02037-3. Epub 2021 Jan 6.
2
Evaluation of a pharmacogenetic-based warfarin dosing algorithm in patients with low time in therapeutic range - study protocol for a randomized controlled trial.低治疗范围内时间患者基于药物遗传学的华法林给药算法评估——一项随机对照试验的研究方案
BMC Cardiovasc Disord. 2016 Nov 17;16(1):224. doi: 10.1186/s12872-016-0405-1.
3
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.达比加群酯与华法林在不同国际标准化比值控制水平下预防心房颤动卒中的疗效和安全性:RE-LY 试验分析。
Lancet. 2010 Sep 18;376(9745):975-83. doi: 10.1016/S0140-6736(10)61194-4.
4
Effect of medication timing on anticoagulation stability in users of warfarin (the INRange RCT): study protocol for a randomized controlled trial.华法林使用者中用药时间对抗凝稳定性的影响(INRange随机对照试验):一项随机对照试验的研究方案
Trials. 2016 Aug 4;17(1):391. doi: 10.1186/s13063-016-1516-9.
5
Dosing options for decreasing the time to achieve therapeutic anticoagulation when reinitiating warfarin: a case series.重新开始使用华法林时,减少达到治疗性抗凝所需时间的剂量选择:病例系列。
Pharmacotherapy. 2011 Aug;31(8):793-805. doi: 10.1592/phco.31.8.793.
6
Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial.低强度与标准强度华法林预防髋或膝关节置换术后静脉血栓栓塞或死亡的效果:一项随机临床试验。
JAMA. 2019 Sep 3;322(9):834-842. doi: 10.1001/jama.2019.12085.
7
Association between apolipoprotein E genotype and warfarin response during initial anticoagulation.载脂蛋白 E 基因型与初始抗凝期间华法林反应的关系。
Biomed Pharmacother. 2018 May;101:251-256. doi: 10.1016/j.biopha.2018.02.095. Epub 2018 Feb 27.
8
Randomized, placebo-controlled trial of orally administered vitamin K1 for warfarin-associated coagulopathy in Chinese patients with mechanical heart valves.随机、安慰剂对照试验:口服维生素 K1 治疗中国机械心脏瓣膜患者华法林相关凝血功能障碍
Eur J Clin Pharmacol. 2021 Sep;77(9):1333-1339. doi: 10.1007/s00228-021-03127-8. Epub 2021 Mar 30.
9
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.与华法林相比,利伐沙班预防非瓣膜性心房颤动合并中度肾功能不全患者的中风和全身性栓塞。
Eur Heart J. 2011 Oct;32(19):2387-94. doi: 10.1093/eurheartj/ehr342. Epub 2011 Aug 28.
10
Effect of oral anticoagulant therapy on mortality in end-stage renal disease patients with atrial fibrillation: a prospective study.口服抗凝治疗对终末期肾病合并心房颤动患者死亡率的影响:一项前瞻性研究。
J Nephrol. 2017 Aug;30(4):573-581. doi: 10.1007/s40620-016-0364-8. Epub 2016 Nov 11.

引用本文的文献

1
Acute kidney injury interacts with VKORC1 genotype on initiative warfarin dose among heart surgery recipients: a real-world research.急性肾损伤与 VKORC1 基因型在心脏手术患者华法林初始剂量中的相互作用:一项真实世界研究。
Sci Rep. 2023 Dec 8;13(1):21750. doi: 10.1038/s41598-023-46895-2.
2
Research Methods and New Advances in Drug-Drug Interactions Mediated by Renal Transporters.药物-药物相互作用的研究方法及肾脏转运体介导的新进展。
Molecules. 2023 Jul 6;28(13):5252. doi: 10.3390/molecules28135252.
3
Influence of Renal Impairment and Genetic Subtypes on Warfarin Control in Japanese Patients.肾功能不全和基因亚型对日本患者华法林控制的影响。
Genes (Basel). 2021 Sep 28;12(10):1537. doi: 10.3390/genes12101537.

本文引用的文献

1
Genotype-Guided Dosing of Warfarin in Chinese Adults: A Multicenter Randomized Clinical Trial.基因指导的华法林在中国成年人中的剂量调整:一项多中心随机临床试验。
Circ Genom Precis Med. 2020 Aug;13(4):e002602. doi: 10.1161/CIRCGEN.119.002602. Epub 2020 Jun 8.
2
Efficacy and Safety of Oral Anticoagulants in Patients With Atrial Fibrillation and Stages 4 or 5 Chronic Kidney Disease.口服抗凝剂在伴有心房颤动和 4 或 5 期慢性肾脏病的患者中的疗效和安全性。
Am J Med. 2019 Nov;132(11):1335-1343.e6. doi: 10.1016/j.amjmed.2019.06.006. Epub 2019 Jul 3.
3
Oral Anticoagulation for Atrial Fibrillation Thromboembolism Prophylaxis in the Chronic Kidney Disease Population: the State of the Art in 2019.2019 年慢性肾脏病患者人群中预防房颤血栓栓塞的口服抗凝治疗:现状。
Cardiovasc Drugs Ther. 2019 Aug;33(4):481-488. doi: 10.1007/s10557-019-06885-x.
4
Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease.阿哌沙班与华法林用于慢性肾脏病伴心房颤动患者的成本-效用分析。
Value Health. 2018 Dec;21(12):1365-1372. doi: 10.1016/j.jval.2018.06.009. Epub 2018 Jul 24.
5
Renal function in patients with mechanical prosthetic valves : Long-term effects of anticoagulation and over-anticoagulation with warfarin.机械人工瓣膜患者的肾功能:华法林抗凝及过度抗凝的长期影响。
Wien Klin Wochenschr. 2018 Jul;130(13-14):436-445. doi: 10.1007/s00508-018-1350-z. Epub 2018 Jun 4.
6
Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction.在伴有肾功能障碍的心房颤动患者中应用口服抗凝剂。
Nat Rev Nephrol. 2018 May;14(5):337-351. doi: 10.1038/nrneph.2018.19. Epub 2018 Mar 26.
7
Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease.替卡格雷和华法林在严重慢性肾脏病患者中的药代动力学。
Thromb Haemost. 2017 Nov;117(11):2026-2033. doi: 10.1160/TH16-10-0815. Epub 2017 Nov 30.
8
A retrospective study on the risk factors for bleeding events in warfarin therapy, focusing on renal function.一项关于华法林治疗中出血事件风险因素的回顾性研究,重点关注肾功能。
Eur J Clin Pharmacol. 2017 Nov;73(11):1491-1497. doi: 10.1007/s00228-017-2316-1. Epub 2017 Aug 9.
9
Warfarin Initiation, Atrial Fibrillation, and Kidney Function: Comparative Effectiveness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation.华法林起始治疗、心房颤动和肾功能:比较新型诊断为心房颤动的老年患者使用华法林的有效性和安全性。
Am J Kidney Dis. 2017 Jun;69(6):734-743. doi: 10.1053/j.ajkd.2016.10.018. Epub 2016 Dec 18.
10
Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.抗栓治疗对伴有慢性肾脏病的心房颤动患者的净临床获益:一项全国性观察性队列研究。
J Am Coll Cardiol. 2014 Dec 16;64(23):2471-82. doi: 10.1016/j.jacc.2014.09.051.

肾功能不全对中国患者华法林抗凝效果及安全性的影响:一项随机对照研究的分析。

Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trial.

机构信息

Center for Clinical Pharmacology, the Third Xiangya Hospital, Central South University, 138 TongZiPo Road, Changsha, 410013, Hunan, China.

Research Center for Drug Clinical Evaluation of Central South University, Changsha, 410013, Hunan, China.

出版信息

Naunyn Schmiedebergs Arch Pharmacol. 2021 Jun;394(6):1275-1283. doi: 10.1007/s00210-020-02037-3. Epub 2021 Jan 6.

DOI:10.1007/s00210-020-02037-3
PMID:33404689
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8208902/
Abstract

This study aimed to analyze the influence of renal insufficiency on the anticoagulant effects and safety of warfarin in Chinese patients. Data on the creatinine levels of participants enrolled in a randomized controlled study were screened and divided into the non-renal insufficiency group, mild renal insufficiency group, and moderate renal insufficiency group, according to the creatinine clearance rate. The primary outcome measures were stable dose and average daily dose of warfarin. Secondary outcome measures were percentage of time in the therapeutic international normalized ratio (INR) (%TTR), and the first time to reach the therapeutic INR. Adverse events included bleeding events, thromboembolic events, and mortality. All participants with renal function test results and a baseline INR of less than 1.5 were included in the primary and secondary outcome analysis. The SPSS Statistics 21.0 software was used for statistical analysis. The randomized controlled trial was registered in Clinicaltrials.gov (NCT02211326). A total of 571 patients were included in this analysis. Multiple regression analysis showed that the renal function was correlated with stable dose, average daily dose, and the first time to reach therapeutic INR after adjusting for confounding factors. However, no correlation was noted between kidney function and %TTR. No significant differences were observed across the various safety parameters among the three groups. Renal function is an important consideration in patients using warfarin.

摘要

本研究旨在分析肾功能不全对中国患者华法林抗凝效果和安全性的影响。对一项随机对照研究中纳入患者的肌酐水平数据进行筛选,并根据肌酐清除率将其分为肾功能正常组、轻度肾功能不全组和中度肾功能不全组。主要观察指标为华法林稳定剂量和平均日剂量。次要观察指标为治疗国际标准化比值(INR)时间百分比(%TTR)和达到治疗 INR 的首次时间。不良事件包括出血事件、血栓栓塞事件和死亡率。所有具有肾功能检测结果和基线 INR<1.5 的患者均纳入主要和次要结局分析。采用 SPSS Statistics 21.0 软件进行统计分析。该随机对照试验已在 Clinicaltrials.gov(NCT02211326)注册。共有 571 例患者纳入本分析。多因素回归分析显示,在调整混杂因素后,肾功能与稳定剂量、平均日剂量和达到治疗 INR 的首次时间相关,但与%TTR 无相关性。三组间各安全性参数无显著差异。肾功能是华法林使用者的重要考虑因素。